Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. (Nasdaq: DMII) is a blank-check company targeting the domestic pharmaceutical manufacturing sector, with its name signaling an explicit focus on onshoring drug production in the United States. The "II" designation marks it as a second SPAC vehicle from the same sponsoring team behind an earlier series vehicle. DMII filed an 8-K with the U.S. Securities and Exchange Commission on April 28, 2026, accession number 0001213900-26-048687, representing a recent regulatory disclosure as the company continues its search for a business combination target in the healthcare and pharma supply chain space. Sign up for SpacDesk to access full filing timelines, status updates, and deal intelligence on DMII and every active SPAC in the market.